Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis

Purpose: To understand the functional and preclinical efficacy of targeting the urokinase plasminogen activator receptor (u-PAR) in ovarian cancer. Experimental Design: Expression of u-PAR was studied in 162 epithelial ovarian cancers, including 77 pairs of corresponding primary and metastatic tumors. The effect of an antibody against u-PAR (ATN-658) on proliferation, adhesion, invasion, apoptosis, and migration was assessed in 3 (SKOV3ip1, HeyA8, and CaOV3) ovarian cancer cell lines. The impact of the u-PAR antibody on tumor weight, number, and survival was examined in corresponding ovarian cancer xenograft models and the mechanism by which ATN-658 blocks metastasis was explored. Results: Only 8% of all ovarian tumors were negative for u-PAR expression. Treatment of SKOV3ip1, HeyA8, and CaOV3 ovarian cancer cell lines with the u-PAR antibody inhibited cell invasion, migration, and adhesion. In vivo, anti-u-PAR treatment reduced the number of tumors and tumor weight in CaOV3 and SKOV3ip1 xenografts and reduced tumor weight and increased survival in HeyA8 xenografts. Immunostaining of CaOV3 xenograft tumors and ovarian cancer cell lines showed an increase in active-caspase 3 and TUNEL staining. Treatment with u-PAR antibody inhibited α5-integrin and u-PAR colocalization on primary human omental extracellular matrix. Anti-u-PAR treatment also decreased the expression of urokinase, u-PAR, β3-integrin, and fibroblast growth factor receptor-1 both in vitro and in vivo. Conclusions: This study shows that an antibody against u-PAR reduces metastasis, induces apoptosis, and reduces the interaction between u-PAR and α5-integrin. This provides a rationale for targeting the u-PAR pathway in patients with ovarian cancer and for further testing of ATN-658 in this indication. Clin Cancer Res; 17(3); 459–71. ©2010 AACR.

[1]  D. Shaw,et al.  An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. , 2010, Neoplasia.

[2]  E. Lengyel.  Ovarian cancer development and metastasis. , 2010, The American journal of pathology.

[3]  E. Kistner,et al.  {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. , 2009, The American journal of pathology.

[4]  K. Patterson,et al.  Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. , 2009, Gynecologic oncology.

[5]  L. Ellis,et al.  Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver , 2009, Cancer.

[6]  R. Alvarez,et al.  Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. , 2009, Gynecologic oncology.

[7]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[8]  A. Mazar.  Urokinase Plasminogen Activator Receptor Choreographs Multiple Ligand Interactions: Implications for Tumor Progression and Therapy , 2008, Clinical Cancer Research.

[9]  E. Lengyel,et al.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. , 2008, The Journal of clinical investigation.

[10]  Aamir Ahmad,et al.  Evolving role of uPA/uPAR system in human cancers. , 2008, Cancer treatment reviews.

[11]  K. Abberton,et al.  Myogel, a Novel, Basement Membrane-Rich, Extracellular Matrix Derived from Skeletal Muscle, Is Highly Adipogenic in vivo and in vitro , 2008, Cells Tissues Organs.

[12]  E. Lengyel,et al.  Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra‐cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum , 2007, International journal of cancer.

[13]  C. Gondi,et al.  Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. , 2007, International journal of oncology.

[14]  E. Kistner,et al.  c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. , 2007, Cancer research.

[15]  H. Chapman,et al.  Urokinase Receptors Are Required for α5β1 Integrin-mediated Signaling in Tumor Cells* , 2006, Journal of Biological Chemistry.

[16]  L. Ellis,et al.  Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. , 2005, Cancer research.

[17]  David G. Morris,et al.  Inhibition of urokinase receptor gene expression and cell invasion by anti‐uPAR DNAzymes in osteosarcoma cells , 2005, The FEBS journal.

[18]  C. Gondi,et al.  RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas , 2004, Oncogene.

[19]  M. Fernö,et al.  High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer , 2003, International journal of cancer.

[20]  R. Mabrouk,et al.  Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma. , 2003, Clinical biochemistry.

[21]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  R. Czekay,et al.  Critical Role of Integrin α5β1 in Urokinase (uPA)/Urokinase Receptor (uPAR, CD87) Signaling* , 2003, Journal of Biological Chemistry.

[23]  P. Carmeliet,et al.  uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.

[24]  R. Hazan,et al.  A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. , 2002, Cancer cell.

[25]  A. Krüger,et al.  High‐affinity urokinase‐derived cyclic peptides inhibiting urokinase/urokinase receptor‐interaction: effects on tumor growth and spread , 2002, FEBS letters.

[26]  C. Borgfeldt,et al.  Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI‐1) , 2001, International journal of cancer.

[27]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[28]  A. Krüger,et al.  High Level Synthesis of Recombinant Soluble Urokinase Receptor (CD87) by Ovarian Cancer Cells Reduces Intraperitoneal Tumor Growth and Spread in Nude Mice , 2001, Biological chemistry.

[29]  D. Doering,et al.  Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[30]  Ivins,et al.  Urokinase-type plasminogen activator in epithelial ovarian cancer: A poor prognostic factor, associated with advanced stage , 1998 .

[31]  C. Zandonella,et al.  Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. , 1996, Cancer research.

[32]  H. Höfler,et al.  Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. , 1995, Cancer research.

[33]  Y. Kook,et al.  The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. , 1994, The EMBO journal.

[34]  B. Gustavsson,et al.  Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. , 1991, European journal of cancer.

[35]  A. Corti,et al.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.

[37]  C. Marshall,et al.  Regulation of cell signalling by uPAR , 2010, Nature Reviews Molecular Cell Biology.

[38]  R. Senekowitsch-Schmidtke,et al.  Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  K. Kilpatrick,et al.  Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist , 2004, Clinical & Experimental Metastasis.

[40]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.